EA200501504A1 - Лиганды каннабиноидных рецепторов и их применение - Google Patents
Лиганды каннабиноидных рецепторов и их применениеInfo
- Publication number
- EA200501504A1 EA200501504A1 EA200501504A EA200501504A EA200501504A1 EA 200501504 A1 EA200501504 A1 EA 200501504A1 EA 200501504 A EA200501504 A EA 200501504A EA 200501504 A EA200501504 A EA 200501504A EA 200501504 A1 EA200501504 A1 EA 200501504A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- receptor ligands
- cannabinoid receptor
- cannabinoid receptors
- ligands
- cannabinoid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Изобретение относится к соединениям формулы (I) и (II), которые действуют в качестве лигандов каннабиноидных рецепторов, и их применению для лечения у животных заболеваний, связанных с вовлечением каннабиноидных рецепторов.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46490803P | 2003-04-23 | 2003-04-23 | |
PCT/IB2004/001357 WO2004094421A1 (en) | 2003-04-23 | 2004-04-13 | Cannabinoid receptor ligands and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200501504A1 true EA200501504A1 (ru) | 2006-04-28 |
Family
ID=33310977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200501504A EA200501504A1 (ru) | 2003-04-23 | 2004-04-13 | Лиганды каннабиноидных рецепторов и их применение |
Country Status (31)
Country | Link |
---|---|
US (1) | US20040214856A1 (ru) |
EP (1) | EP1622903B1 (ru) |
JP (1) | JP2006524225A (ru) |
KR (1) | KR20060006048A (ru) |
CN (1) | CN1809566A (ru) |
AP (1) | AP2005003427A0 (ru) |
AR (1) | AR044037A1 (ru) |
AT (1) | ATE409700T1 (ru) |
AU (1) | AU2004232552A1 (ru) |
BR (1) | BRPI0409791A (ru) |
CA (1) | CA2521538A1 (ru) |
CL (1) | CL2004000827A1 (ru) |
CO (1) | CO5640084A2 (ru) |
DE (1) | DE602004016839D1 (ru) |
EA (1) | EA200501504A1 (ru) |
EC (1) | ECSP056117A (ru) |
ES (1) | ES2309517T3 (ru) |
GT (1) | GT200400076A (ru) |
IS (1) | IS8054A (ru) |
MA (1) | MA27766A1 (ru) |
MX (1) | MXPA05011454A (ru) |
NL (1) | NL1026027C2 (ru) |
NO (1) | NO20055516L (ru) |
OA (1) | OA13047A (ru) |
PA (1) | PA8600601A1 (ru) |
PE (1) | PE20050419A1 (ru) |
TN (1) | TNSN05272A1 (ru) |
TW (1) | TW200510419A (ru) |
UY (1) | UY28276A1 (ru) |
WO (1) | WO2004094421A1 (ru) |
ZA (1) | ZA200508568B (ru) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE375349T1 (de) * | 2002-08-02 | 2007-10-15 | Merck & Co Inc | Substituierte furo(2,3-b)pyridin derivate |
CA2499497A1 (en) | 2002-09-27 | 2004-04-08 | Merck & Co., Inc. | Substituted pyrimidines |
US7094572B2 (en) * | 2003-03-14 | 2006-08-22 | Bristol-Myers Squibb | Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74 |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
CA2524397A1 (en) * | 2003-05-07 | 2004-11-18 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
US7232823B2 (en) * | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US20050026983A1 (en) * | 2003-07-30 | 2005-02-03 | Pfizer Inc | Imidazole compounds and uses thereof |
DE602004024814D1 (de) * | 2003-11-04 | 2010-02-04 | Merck & Co Inc | Substituierte naphthyridinonderivate |
US7151097B2 (en) * | 2003-11-07 | 2006-12-19 | Pfizer Inc. | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
US7589206B2 (en) | 2004-06-09 | 2009-09-15 | Glaxo Group Limited | Pyrrolopyridine derivatives |
US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
MX2007005071A (es) * | 2004-10-27 | 2007-10-03 | Johnson & Johnson | Moduladores de canabinoide de tetrahidro-piridinilpirazol. |
ES2333243T3 (es) * | 2004-12-17 | 2010-02-18 | Eli Lilly And Company | Derivados de tiazolopiridinona como antagonistas del receptor de mch. |
KR20080004559A (ko) | 2005-03-31 | 2008-01-09 | 얀센 파마슈티카 엔.브이. | 테트라하이드로티오피라노 피라졸 카나비노이드 모듈레이터 |
JP2008536909A (ja) * | 2005-04-20 | 2008-09-11 | ファイザー・プロダクツ・インク | カンナビノイド受容体リガンドとしてのアシルアミノ二環複素芳香族化合物 |
EP1890767A2 (en) * | 2005-05-27 | 2008-02-27 | Pfizer Products Inc. | Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss |
EA200800562A1 (ru) * | 2005-08-09 | 2008-06-30 | Глаксо Груп Лимитед | Производные имидазопиридина в качестве лигандов каннабиноидного рецептора |
WO2007046550A1 (en) * | 2005-10-21 | 2007-04-26 | Mitsubishi Tanabe Pharma Corporation | Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity |
EP1986638A2 (en) * | 2006-02-21 | 2008-11-05 | Ampla Pharmaceuticals Inc. | Cb1 antagonists and inverse agonists |
JP2010500300A (ja) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | アリールアミノアリール−アルキル−置換イミダゾリジン−2,4−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用 |
US20080108574A1 (en) * | 2006-09-27 | 2008-05-08 | Braincells, Inc. | Melanocortin receptor mediated modulation of neurogenesis |
PE20090142A1 (es) * | 2007-04-11 | 2009-02-19 | Merck & Co Inc | Derivados de furo[2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1 |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2009097995A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2310372B1 (en) | 2008-07-09 | 2012-05-23 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
JO2870B1 (en) * | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
US8785608B2 (en) | 2009-08-26 | 2014-07-22 | Sanofi | Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
EP2480082A4 (en) | 2009-09-25 | 2014-01-15 | Merck Sharp & Dohme | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OF DIABETES |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120050A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US9365576B2 (en) | 2012-05-24 | 2016-06-14 | Novartis Ag | Pyrrolopyrrolidinone compounds |
US9403827B2 (en) | 2013-01-22 | 2016-08-02 | Novartis Ag | Substituted purinone compounds |
WO2014115080A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
CA2913697A1 (en) | 2013-05-27 | 2014-12-04 | Novartis Ag | Imidazopyrrolidinone derivatives and their use in the treatment of disease |
EA028175B1 (ru) | 2013-05-28 | 2017-10-31 | Новартис Аг | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания |
CA2912991A1 (en) | 2013-05-28 | 2014-12-04 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease |
KR20160086930A (ko) | 2013-11-21 | 2016-07-20 | 노파르티스 아게 | 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도 |
WO2017153601A1 (en) * | 2016-03-11 | 2017-09-14 | Ac Immune Sa | Bicyclic compounds for diagnosis and therapy |
CN105878251B (zh) * | 2016-04-22 | 2019-04-09 | 上海市同济医院 | 帕金森病动物模型的制备方法及其用途 |
EP3630774B1 (en) | 2017-05-31 | 2022-11-23 | ChemoCentryx, Inc. | 5-5 fused rings as c5a inhibitors |
BR112019025049A2 (pt) * | 2017-05-31 | 2020-06-16 | Chemocentryx, Inc. | Anéis 6- 5 fundidos como inibidores de c5a |
SG11202005799XA (en) * | 2017-12-22 | 2020-07-29 | Chemocentryx Inc | DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS |
KR20200109316A (ko) | 2017-12-22 | 2020-09-22 | 케모센트릭스, 인크. | C5aR 억제제로서의 디아릴 치환된 6,5-융합 고리 화합물 |
US11608336B2 (en) * | 2018-04-02 | 2023-03-21 | Chemocentryx, Inc. | Prodrugs of fused-bicyclic C5aR antagonists |
JP2023525081A (ja) * | 2020-05-07 | 2023-06-14 | エーシー・イミューン・エス・アー | 診断のための新規化合物 |
CN117460731A (zh) * | 2021-06-11 | 2024-01-26 | 劲方医药科技(上海)有限公司 | 杂环内酰胺类化合物,其制法与医药上的用途 |
AU2022325748A1 (en) * | 2021-08-11 | 2024-02-22 | Landos Biopharma, Inc. | Tetrahydropyrazolopyridine-analog ligands of nlrx1 and uses thereof |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3340269A (en) * | 1964-09-08 | 1967-09-05 | Ciba Geigy Corp | 1-substituted 4-acyl-2, 3-dioxo-piperidine |
US3365459A (en) * | 1964-09-08 | 1968-01-23 | Ciba Geigy Corp | Certain tetrahydro pyrazolo-pyridine and pyrazolo-piperidine derivatives |
GB8613591D0 (en) * | 1986-06-04 | 1986-07-09 | Roussel Lab Ltd | Chemical compounds |
EP0268554B1 (de) * | 1986-10-22 | 1991-12-27 | Ciba-Geigy Ag | 1,5-Diphenylpyrazol-3-carbonsäurederivate zum Schützen von Kulturpflanzen |
PH27357A (en) * | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
FR2665898B1 (fr) * | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2714057B1 (fr) * | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
US5596106A (en) * | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
FR2741621B1 (fr) * | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
FR2742148B1 (fr) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
ES2213892T3 (es) * | 1997-01-21 | 2004-09-01 | Smithkline Beecham Corporation | Nuevos moduladores del receptor de canabinoides. |
FR2758723B1 (fr) * | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
FR2761266B1 (fr) * | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
KR100652994B1 (ko) * | 1998-09-11 | 2006-11-30 | 아방티 파르마 소시에테 아노님 | 아제티딘 유도체, 이의 제조방법 및 이를 함유하는 약제 |
FR2789079B3 (fr) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
US6653304B2 (en) * | 2000-02-11 | 2003-11-25 | Bristol-Myers Squibb Co. | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
US6355631B1 (en) * | 2000-03-03 | 2002-03-12 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation |
US6566356B2 (en) * | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
US6479479B2 (en) * | 2000-03-03 | 2002-11-12 | Aventis Pharma S.A. | Azetidine derivatives, their preparation and pharmaceutical compositions containing them |
ATE346047T1 (de) * | 2000-03-23 | 2006-12-15 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazolderivate mit cb1- antagonistischer aktivität |
US20020019421A1 (en) * | 2000-07-05 | 2002-02-14 | Roni Biberman | Compositions and therapy for substance addiction |
US20020091114A1 (en) * | 2000-10-04 | 2002-07-11 | Odile Piot-Grosjean | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
AU2002319627A1 (en) * | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
US6509367B1 (en) * | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
US20030139386A1 (en) * | 2001-12-21 | 2003-07-24 | Sophie Cote | Pharmaceutical compositions based on azetidine derivatives |
US6825209B2 (en) * | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
BR0314872A (pt) * | 2002-10-18 | 2005-08-02 | Pfizer Prod Inc | Ligandos do receptor canabinóide e usos dos mesmos |
US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) * | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7329658B2 (en) * | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7176210B2 (en) * | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) * | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
-
2004
- 2004-04-12 US US10/823,152 patent/US20040214856A1/en not_active Abandoned
- 2004-04-13 AP AP2005003427A patent/AP2005003427A0/xx unknown
- 2004-04-13 ES ES04727076T patent/ES2309517T3/es not_active Expired - Lifetime
- 2004-04-13 JP JP2006506562A patent/JP2006524225A/ja not_active Abandoned
- 2004-04-13 MX MXPA05011454A patent/MXPA05011454A/es unknown
- 2004-04-13 CN CNA2004800175674A patent/CN1809566A/zh active Pending
- 2004-04-13 EA EA200501504A patent/EA200501504A1/ru unknown
- 2004-04-13 WO PCT/IB2004/001357 patent/WO2004094421A1/en active IP Right Grant
- 2004-04-13 KR KR1020057020010A patent/KR20060006048A/ko not_active Application Discontinuation
- 2004-04-13 DE DE602004016839T patent/DE602004016839D1/de not_active Expired - Fee Related
- 2004-04-13 BR BRPI0409791-2A patent/BRPI0409791A/pt not_active IP Right Cessation
- 2004-04-13 EP EP04727076A patent/EP1622903B1/en not_active Expired - Lifetime
- 2004-04-13 AT AT04727076T patent/ATE409700T1/de not_active IP Right Cessation
- 2004-04-13 CA CA002521538A patent/CA2521538A1/en not_active Abandoned
- 2004-04-13 OA OA1200500291A patent/OA13047A/en unknown
- 2004-04-13 AU AU2004232552A patent/AU2004232552A1/en not_active Abandoned
- 2004-04-16 CL CL200400827A patent/CL2004000827A1/es unknown
- 2004-04-20 PE PE2004000389A patent/PE20050419A1/es not_active Application Discontinuation
- 2004-04-20 GT GT200400076A patent/GT200400076A/es unknown
- 2004-04-20 PA PA20048600601A patent/PA8600601A1/es unknown
- 2004-04-21 UY UY28276A patent/UY28276A1/es not_active Application Discontinuation
- 2004-04-21 AR ARP040101339A patent/AR044037A1/es unknown
- 2004-04-22 TW TW093111297A patent/TW200510419A/zh unknown
- 2004-04-23 NL NL1026027A patent/NL1026027C2/nl not_active IP Right Cessation
-
2005
- 2005-09-29 IS IS8054A patent/IS8054A/is unknown
- 2005-10-21 TN TNP2005000272A patent/TNSN05272A1/fr unknown
- 2005-10-21 ZA ZA200508568A patent/ZA200508568B/en unknown
- 2005-10-21 EC EC2005006117A patent/ECSP056117A/es unknown
- 2005-10-21 MA MA28565A patent/MA27766A1/fr unknown
- 2005-10-21 CO CO05106974A patent/CO5640084A2/es not_active Application Discontinuation
- 2005-11-22 NO NO20055516A patent/NO20055516L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
OA13047A (en) | 2006-11-10 |
BRPI0409791A (pt) | 2006-05-30 |
CA2521538A1 (en) | 2004-11-04 |
CN1809566A (zh) | 2006-07-26 |
ATE409700T1 (de) | 2008-10-15 |
CL2004000827A1 (es) | 2005-03-04 |
IS8054A (is) | 2005-09-29 |
CO5640084A2 (es) | 2006-05-31 |
MXPA05011454A (es) | 2005-12-12 |
ECSP056117A (es) | 2006-03-01 |
ZA200508568B (en) | 2007-04-25 |
US20040214856A1 (en) | 2004-10-28 |
ES2309517T3 (es) | 2008-12-16 |
AR044037A1 (es) | 2005-08-24 |
NL1026027A1 (nl) | 2004-10-27 |
KR20060006048A (ko) | 2006-01-18 |
GT200400076A (es) | 2004-12-16 |
NO20055516L (no) | 2005-11-22 |
TW200510419A (en) | 2005-03-16 |
AP2005003427A0 (en) | 2005-12-31 |
DE602004016839D1 (de) | 2008-11-13 |
WO2004094421A1 (en) | 2004-11-04 |
UY28276A1 (es) | 2004-11-30 |
TNSN05272A1 (fr) | 2007-07-10 |
EP1622903B1 (en) | 2008-10-01 |
NL1026027C2 (nl) | 2005-07-05 |
PA8600601A1 (es) | 2005-05-24 |
PE20050419A1 (es) | 2005-06-18 |
JP2006524225A (ja) | 2006-10-26 |
AU2004232552A1 (en) | 2004-11-04 |
EP1622903A1 (en) | 2006-02-08 |
MA27766A1 (fr) | 2006-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200501504A1 (ru) | Лиганды каннабиноидных рецепторов и их применение | |
EA200501771A1 (ru) | Лиганды каннабиноидных рецепторов и их применения | |
EA200501430A1 (ru) | Лиганды каннабиноидных рецепторов и их применение | |
EA200301215A1 (ru) | Лиганды рецепторов 5-ht и их применение | |
EA200500520A1 (ru) | Пуриновые соединения и их применение в качестве лигандов каннабиноидных рецепторов | |
CY1109998T1 (el) | Ενδυναμωτες υποδοχεων γλουταμινικου | |
EA200602243A1 (ru) | 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов | |
MXPA05007938A (es) | Ligandos de receptores de cannabinoides y usos de los mismos. | |
TW200503723A (en) | Cannabinoid receptor ligands and uses thereof | |
MXPA05011922A (es) | Ligandos del receptor de cannabinoides y sus usos. | |
EA200602242A1 (ru) | 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов | |
EA200601895A1 (ru) | 3-(4-гетероарилциклогексиламино)циклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов | |
EA200802213A1 (ru) | Способы лечения заболеваний крови | |
EA200601798A1 (ru) | Замещенные соединения морфолина для лечения расстройств центральной нервной системы | |
EA200300829A1 (ru) | Производные 1-арил- или 1-алкилсульфонилбензазола в качестве лигандов 5-гидрокситриптамина-6 | |
NO20073182L (no) | Indazol-karboksamidforbindelser | |
EA200700225A1 (ru) | Аналоги тетрапептида | |
DE602005014566D1 (de) | Chinolinon-carboxamid-verbindungen | |
EA201071264A1 (ru) | Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера | |
ATE441646T1 (de) | 5-ht4-rezeptoragonistenverbindungen | |
EA200700047A1 (ru) | Новые алкильные производные в качестве метаботропных рецепторов глутамата | |
WO2007020502A3 (en) | Cannabinoid receptor ligands and uses thereof | |
ECSP055964A (es) | Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6 | |
EA200600647A1 (ru) | Соединения бициклических пиразолила и имидазолила и их применение | |
EA200801220A1 (ru) | 3-аминоциклопентанекарбоксамиды в качестве модуляторов хемокиновых рецепторов |